logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn files modified protocol for Leronlimab trial battling respiratory complications as a result of contracting Coronavirus

CytoDyn (OTCQB: CYDY) President and CEO Nader Pourhassan joined Steve Darling from Proactive Vancouver to discuss the company filing a modified protocol of their Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients with Coronavirus. 

Pourhassan telling Proactive that new protocol is for 75 planned patients in up to 10 centres in the United States. Patients enrolled in the trial are expected to have a treatment window of approximately 6 weeks.


 

Quick facts: CytoDyn Inc.

Price: 2.31 USD

OTCMKTS:CYDY
Market: OTCQB
Market Cap: $999.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn reports early but strong clinical responses for two...

CytoDyn (OTCQB:CYDY) President Nader Pourhassan joined Steve Darling from Proactive Vancouver to discuss continued promising clinical responses from its metastatic triple-negative breast Phase1b/2 trial and its trial investigating leronlimab for the treatment of metastatic breast...

on 6/1/20

2 min read